Nandini Rudra-Ganguly

机构：AbbVie (United States)

发表论文 42 篇 · 总被引 464 次 · h-index 10

代表论文

• 1439P ABBV-400, a c-Met protein–targeting antibody-drug conjugate (ADC), in patients (pts) with advanced gastric/gastroesophageal junction adenocarcinoma (GEA): Results from a phase I study (2024 · Annals of Oncology · 被引 9)
• 1318MO First-in-human study of ABBV-637, an EGFR-targeting BCL-XL–inhibiting antibody-drug conjugate combined with osimertinib (OSI) in relapsed/refractory, EGFR-mutated non-small cell lung cancer (NSCLC) (2023 · Annals of Oncology · 被引 8)
• P3.13D.09 Prevalence and Prognostic Impact of SEZ6 Expression in a Real-World Cohort of Patients with Small-Cell Lung Cancer (2024 · Journal of Thoracic Oncology · 被引 2)
• Telisotuzumab Adizutecan (ABBV-400), a Novel c-Met–Targeting Antibody–Drug Conjugate: First-in-Human Results in Advanced Gastric/Gastroesophageal Junction Cancer (2026 · Clinical Cancer Research · 被引 1)
• Telisotuzumab adizutecan (ABBV-400; Temab-A) in combination with fluorouracil, leucovorin, and budigalimab in locally advanced/metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (a/m GEA). (2025 · Journal of Clinical Oncology · 被引 1)
• Biomarkers of response in patients with gastric/gastroesophageal junction adenocarcinoma (GEA) treated with telisotuzumab adizutecan. (2025 · Journal of Clinical Oncology · 被引 1)